Our results suggest that the HDAC inhibitor CG200745 causes epigenetic reactivation of critical genes that are transcriptionally suppressed in cancers, and therefore can be a promising NSCLC cancer therapeutic. This evidence concerns the gene HDAC9 and cancer.